HI
AMLX icon

Harbour Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Harbour Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25K Hold
90
– – ﹤0.01% 4045
2025
Q4 		$1.09K Hold
90
– – ﹤0.01% 3443
2025
Q3 		$1.22K Hold
90
– – ﹤0.01% 3386
2025
Q2 		$577 Hold
90
– – ﹤0.01% 3349
2025
Q1 		$319 Hold
90
– – ﹤0.01% 3388
2024
Q4 		$340 Buy
+90
New +$424 ﹤0.01% 3324

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Harbour Investments's AMLX Position: Q1 2026 in Review

Harbour Investments held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 90 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #4045.

Harbour Investments first reported a position in AMLX in Q4 2024 and has held it in 6 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Harbour Investments held 90 shares of Amylyx Pharmaceuticals worth $1.25K as of Q1 2026.
  • Harbour Investments left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4045 holding.
  • Harbour Investments first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.